/
Pharma-Bio Serv, Inc. ( Pharma-Bio or the Company ) is a Delaware corporation organized on January 14, 2004. The Company operates in Puerto Rico, the United States, Europe and Brazil under the name of Pharma-Bio Serv, and is engaged in providing technical compliance consulting services to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied prod…
$0.50
+$0.00 (+0.00%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-7.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 5.3% YoY. The question is whether this is cyclical or a structural shift.
At 167x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -$222K. The business is consuming cash, not generating it.
166.7x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9M
▼ -5.3% YoY
Net Income (TTM)
$61K
▲ +87.1% YoY
Op. Margin
-4.36%
▲ +6.5pp YoY
ROIC
-2.81%
▲ +2.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$246K
▲ +69.5% YoY
Op. Cash Flow (TTM)
-$239K
▲ +62.1% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
5Y CAGR: -16.0%
Continue Research
At a P/E of 166.7, A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Pharma-Bio Serv scores 22/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 15.0%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Pharma-Bio Serv scores 22 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -4.4% operating margin and a -2.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Pharma-Bio Serv pays a regular dividend of about $0.08 per share per year (typically in quarterly installments), a yield of roughly 15.0% at the current price. That is a payout ratio of about 2,796.9% of earnings, so the dividend is stretched at this level. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For PBSV's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh PBSV's valuation and scores 22/100 on quality (lower-quality). It also yields about 15.0%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.